IUdR/BUdR Cell Cycle Labelling

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Histologic proof of one of:

• AML, ALL, or AUL

• MDS or CMML

• CML

• OR undergoing bone marrow transplantation.

Participants should be:

• off therapy for at least two weeks

• At least 18 years old or older

• Using adequate contraception if of child-bearing capability.